Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Receivables (2016 - 2025)

Ultragenyx Pharmaceutical has reported Receivables over the past 11 years, most recently at $2.0 million for Q4 2025.

  • Quarterly Receivables fell 98.39% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, down 98.39% year-over-year, with the annual reading at $2.0 million for FY2025, 98.39% down from the prior year.
  • Receivables was $2.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $3.8 million in the prior quarter.
  • Over five years, Receivables peaked at $125.4 million in Q2 2025 and troughed at $2.0 million in Q4 2025.
  • The 5-year median for Receivables is $37.0 million (2022), against an average of $44.9 million.
  • Year-over-year, Receivables soared 233.73% in 2024 and then plummeted 98.39% in 2025.
  • A 5-year view of Receivables shows it stood at $44.4 million in 2021, then dropped by 23.7% to $33.9 million in 2022, then increased by 18.88% to $40.3 million in 2023, then soared by 207.69% to $124.0 million in 2024, then plummeted by 98.39% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Receivables are $2.0 million (Q4 2025), $3.8 million (Q3 2025), and $125.4 million (Q2 2025).